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Both the core JAK-STAT pathway components and their in vivo roles have been widely conserved between vertebrates
and invertebrate models such as Drosophila melanogaster. Misregulation of JAK-STAT pathway activity has also been
identified as a key factor in the development of multiple human malignancies. Recently, whole genome RNA interference
(RNAi) screens in cultured Drosophila cells have identified both positively and negatively acting JAK-STAT pathway
regulators. Here, we describe the analysis of 73 human genes representing homologs of 56 Drosophila genes originally
identified by genome-wide RNAi screening as regulators of JAK-STAT signaling. Using assays for human STAT1 and STAT3
protein levels and phosphorylation status, as well as assays measuring the expression of endogenous STAT1 and STAT3
transcriptional targets, we have tested siRNAs targeting these 73 human genes and have identified potential JAK-STAT
pathway regulatory roles in 69 (95%) of these. The genes identified represent a wide range of human JAK-STAT pathway
regulators and include genes not previously known to modulate this signaling cascade. These results underline the value
of model system based approaches for the identification of pathway regulators and have led to the identification of loci
whose misregulation may ultimately be implicated in JAK-STAT pathway-mediated human disease.
Introduction
The accurate, timely and proportionate regulation of a small
number of evolutionarily conserved signal transduction cascades
is essential for embryonic development and adult life.1 However,
while the components central to most signaling pathways have
been identified, the regulators of pathway activity required in
vivo are less well known. One example of such a signal trans-
duction pathway is the JAK-STAT signaling cascade, named after
its two central components, the Janus kinase (JAK) and the
Signal Transducer and Activator of Transcription (STAT).2,3
In vertebrates, four JAK-like genes (JAK1–3 and Tyk2) and
seven STAT transcription factors (STAT1–4, 5a, 5b and 6) have
been identified. These have been shown to function in a range
of processes including development, cellular proliferation and
response to infection.2 In the canonical model of pathway
activation, binding of an extracellular ligand to a trans-membrane
receptor activates a receptor-associated JAK tyrosine kinase.
Following activation, JAK phosphorylation of the receptor
complex provides docking sites for STAT transcription factors,
which are themselves phosphorylated on a conserved C-terminal
tyrosine residue. STAT molecules activated in this manner
translocate to the nucleus where they bind to DNA within the
promoters of pathway target genes to activate transcription.4
In vertebrates, JAK-STAT pathway signaling can be modulated
by many different ligands leading to the specific activation of
STATs with distinct biological consequences. For example, the
interferon family of ligands activates STAT1 and STAT2 via
JAK1 and JAK2. This in turn induces the expression of target
genes including GBP1 and other cytokines.5 The cellular func-
tions mediated by STAT1 include potent anti-proliferative and
pro-apoptotic responses, tumor immuno-surveillance6 and res-
ponses to viral infection.7 By contrast, constitutive activation of
STAT3, as well as STAT5A and 5B, can result in oncogenic
cellular responses with multiple tumors and tumor-derived cell
lines displaying high levels of phosphorylated-STAT3 activity.8
During normal cellular processes, ligands such as Interleukin 6
(IL-6) and Oncostatin M (OSM), also acting via JAK1, lead to
STAT3 phosphorylation and the expression of specific target
genes including SOCS3.9 Interestingly, the proliferative and anti-
proliferative functions performed by different STATs in verte-
brates can be exerted by the single STAT protein present in
Drosophila melanogaster.10
In addition to the core pathway components, ligands and
receptors a number of ‘non-core’ pathway regulators have also
been identified. These include the SOCS proteins, such as the
pathway target gene SOCS3, which act to negatively regulate the
stimulated receptor/JAK complex forming negative feedback loops
*Correspondence to: Martin P. Zeidler; Email: m.zeidler@sheffield.ac.uk
Submitted: 06/02/11; Revised: 08/26/11; Accepted: 09/06/11
http://dx.doi.org/10.4161/jkst.18006
JAK-STAT 1:1, 34–43; January/February/March 2012; G 2012 Landes Bioscience
34 JAK-STAT Volume 1 Issue 1
© 2012 Landes Bioscience.
Do not distribute.
that reduce the duration and intensity of pathway activation.11
In addition, the PIAS proteins and the SHP1/2 tyrosine phos-
phatases also act as negative regulators of pathway activity.12
However, although understanding of these factors has advanced
significantly in recent years, a comprehensive search for novel
modulators of vertebrate pathway activity has not been under-
taken and it remains likely that a number of regulatory mechan-
isms are yet to be identified.
To circumvent the difficulties inherent in screening the
vertebrate genome for regulators of the high complexity and
semi-redundant JAK-STAT pathway, we have previously used
Drosophila melanogaster to undertake a whole-genome cell culture
based RNAi screen. This approach led to the identification and
validation of 90 Drosophila regulators of JAK-STAT pathway
signaling including 66 positive and 24 putative negative pathway
regulators. Many of these show in vivo, genetic and molecular
interactions consistent with their proposed role in pathway
signaling.13 One of the central tenets of this approach was the
anticipation that low levels of genetic redundancy within the
Drosophila genome would allow the identification of factors that
might not otherwise be detected in similar vertebrate screens. At
the same time, it was anticipated that the regulatory activities
identified in Drosophila would have been evolutionary conserved
with homologous gene-products exerting specific effects on the
JAK-STAT pathways of vertebrate systems.
In this report we ask whether factors important for JAK-STAT
signal transduction in Drosophila are required for the activity
of one or more of the STATs that make up the human pathway.
We identified 73 human genes, which represent putative homo-
logs of 56 Drosophila genes previously identified as pathway
modulators.13 Using siRNA approaches in human HeLa cells, we
knocked down the activity of these genes and, using phosphory-
lation and transcriptional assays for STAT1 and STAT3, have
identified 67 human pathway regulators. The loci identified
include genes encoding components of the endocytic machinery,
chromatin remodeling enzymes and protein-modifying enzymes,
which may provide post-translational modifications important
for pathway activity.
This study highlights the strength of systematic cross-species
approaches for the identification of cancer-pathway regulators and
serves as a starting point for future analysis of potential disease-
related molecules.
Results
STAT phosphorylation assays. One essential pre-requisite for
canonical JAK-STAT pathway activity is the phosphorylation of a
conserved tyrosine (Y) residue present in the C-terminal region of
all STAT transcription factors. This post-translational modifica-
tion is both essential for, and indicative of, pathway activation.14
Using HeLa cells as a tractable and representative human cancer-
derived cell line, we therefore set out to assess the phosphoryla-
tion state of endogenous STAT1 and STAT3 as stimulated by
upstream pathway components and receptors endogenously
expressed in these cells. Both STAT1 and STAT3 are expressed
in unstimulated cells with STAT3 S726 phosphorylation15 and
low levels of STAT3 Y705 phosphorylation also detected in the
absence of exogenous ligand (Fig. 1A). In order to determine the
most appropriate pathway ligands we treated cells with IL-2, IL-3,
IL-6, IL-6 with soluble IL-6 receptor (IL-6R), Interferon gamma
(IFN-c) and OSM for 15 min (Fig. 1A). While stimulation with
IL-2 and IL-3 have no effect on either STAT, IL-6 + IL-6R,
IFN-c and OSM all result in a strong increase in the relative level
of STAT1 phospho-Y701 (pSTAT1). Similarly, stimulation with
IL6, IL-6 + IL-6R and OSM causes the phosphorylation of
Y705 of STAT3 (pSTAT3). Based on these results we therefore
focused on IFN-c as a mediator of STAT1 stimulation and OSM
as a mediator of STAT3.
In order to check the feasibility of using siRNA-mediated
knockdown of JAK-STAT pathway regulators in conjunction
with pSTAT1 and pSTAT3 assays we also set up experiments
using either control siRNAs or siRNA pools knocking down
known pathway components. Allowing 3 d for protein depletion,
JAK1 knockdown reduces the intensity of both pSTAT1 and
pSTAT3 detectable after ligand stimulation while siRNAs
targeting the individual STAT transcripts specifically reduce both
phosphorylated and non-phosphorylated forms (Fig. 1B and C)
indicating that knockdown of genes known to modulate STAT
phosphorylation can be identified by this approach.
It should however be noted that although tyrosine phosphory-
lation of STATs is required, it is not necessarily sufficient for
transcriptional activity. Other post-translational modifications
have been identified that modulate the transcriptional potential of
activated STAT molecules.14 Conversely, constitutively phospho-
rylated dominant-negative mutations of Drosophila STAT92E
have also been identified that are incapable of stimulating target
gene transcription.16
Transcriptional assays. Although tyrosine phosphorylation of
vertebrate STATs is essential for their activity, the principal
biological consequence of JAK-STAT pathway stimulation is a
change in pathway target gene expression.5,17 We therefore set
out to measure the expression of endogenous target genes driven
by native promoters in their normal chromatin context, thereby
avoiding the limitations of transiently transfected reporters.13 We
first tested nine endogenous genes previously reported to be
STAT transcriptional targets5 for their potential suitability as
pathway activity reporters. We stimulated with IL-6 and OSM to
activate STAT3 and IFN-c to activate STAT1 target genes and
measured mRNA levels expressed relative to β-ACTIN (Fig. 2A).
Of the target genes tested, IFN-c-induced GBP1 and OSM-
induced SOCS3 expression were most suitable as reporters for
STAT1 and STAT3 activity respectively. However, while large
increases in GBP1 expression are elicited by IFN-c stimulation,
the fold increase in SOCS3 expression elicited by OSM is less,
with IFN-c also leading to increased SOCS3 mRNA levels
(Fig. 2A). The increase in the signal: noise ratio resulting from
lower levels of SOCS3 expression, and as well as potential inter-
pathway cross-talk must therefore be taken into account when
analyzing results derived from this assay.
We then set out to test the efficacy of siRNA-induced
knockdown on GBP1 and SOSC3 transcription. As expected,
knockdown of JAK1 and JAK2 significantly reduces expression of
RESEARCH PAPER
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both target genes (Fig. 2B). Similarly, as would be expected of a
bona fide target gene, knockdown of STAT1 strongly reduces
expression of GBP1 while knockdown of STAT3 reduces the
levels of OSM induced SOCS3 expression. However, a degree of
crosstalk/redundancy is evident with the levels of OSM-induced
SOCS3 mRNA falling following STAT1 knockdown while the
level of IFN-c-induced GBP1 increases following a reduction in
STAT3 levels.
Intriguingly, compensatory mechanisms and crosstalk between
JAK-STAT pathway components is also demonstrated by the
knockdown of STAT5A and STAT5B as well as JAK3 which all
result in statistically significant (p , 0.05) increases in IFN-c-
induced GBP1 expression. Consistent with these findings, it has
been reported that activated STAT5 can protect cells from IFN-
c-induced apoptosis18 and that overexpression of STAT5 can
counteract interferon signaling.19 However, the molecular basis of
this interaction remains to be established.
Interestingly, while STAT5A and STAT5B are highly
homologous at the protein level, OSM-induced SOCS3 mRNA
is modulated in opposite directions following knockdown of these
two closely related molecules (Fig. 2B).
Identification of human homologs. We recently identified 90
JAK-STAT pathway-regulating genes in a whole-genome RNAi
based screen in Drosophila Kc167 cells.13 In order to identify
potential human homologs we used HomoloGene, Inparanoid
and best reciprocal BLAST searches as parsed from the Flight
database (http://flight.licr.org)20 and identified 73 human can-
didate genes representing homologs of 56 interacting Drosophila
genes (Table 1). This collection includes controls such as STAT1,
STAT3 and JAK1 as well as previously uncharacterized loci. In
order to address the potential role of these genes, siRNA pools
targeting each transcript with four independent 21-mers were
used to maximize the chance of effective knockdown while
minimizing potential off-target effects.21
Screening for human JAK-STAT pathway regulators. Having
developed assays and identified the human homologs of interact-
ing Drosophila genes we then tested all 73 siRNA-pools for their
influence on STAT1 and pSTAT1 as well as STAT3, pSTAT3
Figure 1. STAT phosphorylation as a reporter for regulatory factors. (A) Antibodies detecting pSTAT1 and STAT1 (top two panels) as well as pSTAT3 and
STAT3 (bottom 3 panels) were used to assess the effect of stimulation with the cytokines shown. (B) The effect of the indicated siRNAs on the levels of
pSTAT1 and total STAT1 following IFN-c stimulation as indicated. Note the loss of STAT1 following treatment with STAT1 siRNA and the reduction in
pSTAT1 levels following knockdown with JAK1 siRNA. (C) The effect of the indicated siRNAs on the levels of pSTAT3 and total STAT3 following OSM
stimulation as indicated. (D and E) The effect of the indicated siRNAs on the levels of pSTAT1 and total STAT1 following IFN-c stimulation (D) and pSTAT3
and STAT3 following OSM stimulation (E).
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and β-ACTIN levels following a 3 d knockdown protocol
(Table 2 and Fig. 1D and E). Using the levels of β-ACTIN as a
reference, the levels of total and phosphorylated STATs were
measured (see Materials and Methods) and expressed as fold
changes relative to controls run in parallel on the same protein gel
blot (Table 2). Changes in the overall levels of unphosphorylated
STAT1 and STAT3 as well as the level of pSTAT1 and pSTAT3
are indicated with increases highlighted in green and decreased
levels in red. A subset of tested loci is shown in Figure 1D and E.
Genes were identified that affected the overall levels of STAT1
and/or STAT3, the level of pSTAT1/pSTAT3 or the levels of
both overall and phosphorylated STATs.
We next assayed the effects of the 73 siRNA pools on IFN-c
and OSM-stimulated target gene expression. Following treatment
with siRNA for 3 d and stimulation with either IFN-c or OSM
for 6 h, cells were lysed and RNA prepared. The level of GBP1
and SOCS3 mRNAs expressed from their endogenous loci were
detected by qPCR and normalized to β-actin mRNA levels. This
was expressed as a fold change relative to cells treated with a
control siRNA (Fig. 3A). Triplicate experimental replicates were
used to calculate the mean change in gene expression (Fig. 3A).
Overall 57 genes (excluding the known pathway components
shown in Fig. 2B) produced significant changes in either GBP1 or
SOCS3 expression. As shown in Figure 3A, genes were clustered
into groups on the basis of their differential gene regulation
representing loci that upregulate GBP1 (group a, c and d), or
SOCS3 (group a and b), regulate only one target gene (group
b, c, e and g) or differentially regulate expression in opposite
directions (group d). The identity and potential roles of some of
these STAT-regulating loci are discussed in greater detail below.
Strikingly however, a greater number of STAT1-interacting v.
STAT3-interacting loc were identified by both transcriptional
and phosphorylation assays. While the reagents/assays for STAT1
activation are better than for STAT3 (note the comparatively
lower background following STAT1 knockdown in Figs. 1D and
2B) it is unlikely that this is the only explanation and further
investigation into the mechanisms underlying this observation
will be required.
Discussion
We have identified 73 putative human homologs (Table 1) of
53 Drosophila JAK-STAT pathway modulators originally iden-
tified by whole-genome RNAi screening.13 Using a combination
of protein phosphorylation (Fig. 1) and transcriptional assays
(Fig. 2) we examined STAT1 and STAT3 activity following
knockdown of these 73 human homologs in HeLa cells to assess
potential evolutionary conservation of their pathway modulating
function. Overall, phosphorylation assays identified 39 modifiers
of STAT1 and 19 modifiers of STAT3 (Table 2) while trans-
criptional assays identified 57 loci that significantly modulate the
expression of endogenous STAT1 and/or STAT3 target genes
(Fig. 3A). In total, 69 of the 73 human genes (95%) showed an
interaction indicating that the majority of genes whose primary
sequence has been conserved have also retained their functional
biological roles during the evolutionary divergence that separates
Drosophila and humans. It should however be noted that more
detailed study in multiple human cell lines will ultimately be
needed to confirm the role of these interacting genes in the wider
human context.
The conservation of gene function between related STAT-
regulators present in both humans and Drosophila demonstrates
that it is feasible to use Drosophila as a relevant and tractable
system for gene discovery approaches that can be applied to
humans. This utility is especially striking given the significant
differences in genomic and proteomic complexity between the
two organisms. Indeed, well-characterized cellular processes such
as endocytosis are frequently regulated by multiple closely related
semi-redundant factors. For example, while Drosophila contains
a single Rab5 protein,22 vertebrate trafficking utilizes three
Figure 2. Assays for STAT-mediated transcriptional regulation. (A) Fold
increase in the mRNA levels of the indicated putative STAT target genes
following stimulation with the indicated ligands. (B) Fold increase in the
mRNA levels of GBP1 (black bars) and SOCS3 (gray bars) following
stimulation with IFN-c and OSM respectively. Cells were previously
treated with the indicated siRNAs targeting known JAK-STAT pathway
components and demonstrate the specificity of these target genes for
STAT1 and STAT3 as well as the compensatory effects that result from
the knockdown of other related factors. Statistical significance is
indicated by **p , 0.01, ***p , 0.001. Error bars show standard error.
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homologous Rab5-like proteins, Rab5A, Rab5B and Rab5C.
Furthermore, removal/knockdown of all three is required to block
endocytosis in cultured cells23 suggesting a significant level of
redundancy. Despite this apparent redundancy, individual knock-
down of each Rab5-like gene produces distinct transcriptional
JAK-STAT phenotypes with loss of Rab5A leading to an increase
in STAT1, loss of Rab5B an increase in STAT1 and a decrease in
STAT3, and Rab5C producing no effect (Fig. 3B). Consistent
with a link between endocytosis and STAT activity, STAT1-
mediated signaling induced by IFN-c has recently been shown to
Table 1. Homolog selection
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be differentially regulated depending on the Clathrin-dependent
or Clathrin-independent route via which receptor endocytosis
occurs.24 Our results suggest that the situation may be more
complex and suggests that the Rab5 family proteins required for
Clathrin dependent endocytosis perform distinct roles and that
disruption of these roles is sufficient to modulate the activity of at
least two independent STAT molecules.
Another striking phenotype observed is the strong upregula-
tion of both GBP1 and SOCS3 mRNA following knockdown of
UBR1 (Fig. 3B). UBR1 is a key component of the N-end rule
machinery, a conserved cellular process that affects protein
stability on the basis of the N-terminal amino acid. Substrates
of the N-end rule are recognized by the UBR1 E3-ubiquitin
ligase25 and the increase in STAT1 and STAT3 activity that
occurs following its knockdown suggests that a positively acting
pathway components may represent UBR1 substrates. Although
the overall level of STAT proteins does not appear to be directly
affected by knockdown of UBR1 (Table 2) it would be interesting
to test other JAK-STAT pathway components and other elements
of the N-end rule machinery to examine a potential link between
these two cellular processes.
One of the key aspects of the STAT1 and STAT3 transcrip-
tional assay development was the decision to avoid transiently
transfected reporter assays in preference for the direct measure-
ment of pathway target gene mRNA expressed by endogenous
promoters from within their normal chromatin context (Fig. 2).
This is especially relevant in the light of recent reports from
Drosophila, which suggest that chromatin structure may be
directly linked to JAK-STAT pathway activity via a direct physi-
cal interaction of STAT92E with Heterochromatin Protein 1
(HP1).26,27 Consistent with this, human JAK2 has also recently
been suggested to modify chromatin via direct phosphorylation of
Histone H3, so interfering with HP1 association.28 Consistent
with such interactions, this screen has also identified a number of
putative regulators of heterochromatin (Fig. 3C). These include
SUPT16H, a component of the FACT complex required for
transcription from chromatinized DNA29 as well as RBBP4, a
member of the histone deacetylase complex30 and RBBP5 a key
component of the H3K4 methyltransferase complex.31 Although
preliminary, it will be intriguing to determine the significance of
these interactions in the context of STAT-mediated transcription
and chromatinization in the future.
Table 2.
*NA, not available due to low b-actin levels; light green, . 1.67-fold higher; green, . 2.2-fold higher; pink, , 0.6-fold higher; red, , 0.45-fold higher.
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Figure 3. Screening for JAK-STAT modulating genes by qPCR. (A) Heat map showing the level of IFN-c induced GBP1 mRNA and OSM induced SOCS3
mRNAs expressed following knock down of the indicated genes. Numbers represent the fold change relative to controls. Colors represent statistically
significant increases (reds) or decreases (blues) in expression with dark red/blue p , 0.001 and light red/blue p , 0.05. Genes have been grouped
according to phenotype and are discussed in the main text. (B and C) Graphs representing the interactions of genes falling into predicted endocytosis
and protein stability (B) or chromatin modifier (C) ontologies. Error bars show standard error. *p , 0.05, **p , 0.01, ***p , 0.001.
40 JAK-STAT Volume 1 Issue 1
© 2012 Landes Bioscience.
Do not distribute.
Although this screen has identified several intriguing interac-
tions, it is not generally feasible to individually verify the deple-
tion of individual proteins following siRNA-mediated knockdown
in large scale screens. However, the high proportion of loci with
STAT-modulator phenotypes suggests that most siRNA pools
are indeed effective. While the efficiency of siRNA targeting
STAT1 and STAT3 has been directly demonstrated (Fig. 1B),
it remains possible that false negatives, caused by a failure to
reduce protein levels, or false positives caused by off-target
effects, may be present. Ultimately, further biological characteri-
zation of the interactors identified will be required. In addition,
while both STAT phosphorylation and transcriptional activity
have been widely used as proxies for pathway activity in the
past,5,17,32,33 our experience suggests that neither is necessarily
consistent in isolation. Indeed, we have identified genes whose
knockdown appears to modulate phosphorylation and transcrip-
tion in different directions, genes that modulate phosphorylation
without changing transcription, and genes that affect transcription
without any apparent effect on STAT phosphorylation. Thus,
while both approaches are valid, more detailed analysis of protein
function will be required before mechanistic interactions can be
proven.
In summary, we have demonstrated that whole genome
screening approaches in low complexity animal models are able
to generate potential lead candidates highly enriched for genuine
regulators of the corresponding vertebrate pathway. Knowledge
of the potential molecular mechanisms by which these human
genes mediate their effects will be important in understanding
and ultimately treating the human diseases that arise from the
misregulation of this signaling pathway.
Materials and Methods
Selection of homologs. The 90 previously identified Drosophila
modulators13 were systematically screened for potential homologs
using HomoloGene, Inparanoid and best BLAST homologs
parsed from the Flight database20 (http://flight.licr.org).
Cell culture. HeLa SS6 cells (a kind gift from Jens Gruber and
Mary Osborn) were maintained in D-MEM [including 4.5 mg/
ml glucose, L-glutamine and pyruvate (Gibco)] with 10% heat
inactivated fetal bovine serum (PAA) and penicillin-streptomycin
(Invitrogen). Cells were grown at 37°C in a humidified incubator
with 5% CO2 at subconfluent densities. HeLa cells were stimu-
lated with recombinant human IFN-c (R&D Systems, 40 ng/ml)
or OSM (R&D Systems, 20 ng/ml).
siRNAs. ‘Smart pool’ siRNAs (Dharmacon RNA Technolo-
gies) targeting the transcripts of each locus (Table 1) consisted of
a pool of four independent dsRNAs designed to maximize the
chance of effective knockdown while minimizing potential off-
target effects. siRNA transfections of HeLa SS6 cells were per-
formed with Oligofectamine (Invitrogen) with 50 nM siRNA in
96-well plates.
Detection of target gene activity. Gene expression levels in
human cells were quantitatively measured using either a branched
DNA assay (QuantiGene, Panomics) or quantitative PCR (qPCR)
approaches, both of which gave comparable results. HeLa cells
were grown to confluence in 96-well plates and lysed in 100 ml
proprietary lysis buffer. Seventy microliters of lysate were used for
determination of all mRNA levels except for β-ACTIN, where
only 10 ml were used. Mixed probe sets were added to the lysates
according to the manufacturer’s instructions and hybridized in
sealed capture plates. Following overnight hybridization at 56°C,
capture plates were washed before incubation with 100 ml per
well label extender for 1 h at 56°C. After further washing, plates
were incubated with 100 ml per well amplifier for 1 h at 56°C,
washed three times and finally incubated with 100 ml per
well substrate for 30 min. Plates were cooled down at room
temperature for 10 min, and luminescence was detected for
0.2 sec per well on a luminometer (Wallac Victor Light 1420
Luminescence Counter, PerkinElmer).
HeLa cells were plated at a density of 5  103 cells per well in
a 96-well plate. Next day, these cells were treated with 50 nm
concentration of different siRNAs. After 3 d, the cells were than
treated with human IFN-c (R&D Systems, 40 ng/ml) or OSM
(R&D Systems, 20 ng/ml) for 6 h, lysed in 100 ml of lysis buffer
according to the manufacturer’s instructions (Qiagen RNeasy
Mini kit). Total RNA was prepared and first strand cDNA
was synthesized using First Strand Synthesis Verso cDNA kit
(ABgene).
Real-time PCR was performed in 96-well plates using ABsolute
QPCR ROX mix and a GeneAmp 7700 sequence detector
(Applied Biosystems) and analyzed by DDCT.GBP1 and SOCS3
levels were normalized to β-actin levels. Primers and probes were
designed using Primer Express Software (Applied Biosystems).
BLAST searches (www.ncbi.nlm.nih.gov) were performed to con-
firm specificity of the nucleotide sequences. Primers and probes
were synthesized by Sigma Aldrich and were from 5' to 3' as
follows: For GBP1: GCCAGGCCACATCCTAGTTCT and
GGCGAAGATCCAGGAGTCATT, probe TGGACACCGA-
GGGTCTGGGAGATGT. For SOCS3: AGCTGGTCTCCT-
TTTCCTACTCATACTA and GGTGAAAGATGTCCCGTC-
TCC, probe TGGGTGGATGGAGCGGGAGGA and for
β-actin: ATCATTGCTCCTCCTGAGCG and GACAGCGAG-
GCCAGGATG, probe TACTCCGTGTGGATCGGCGGCT.
Detection of STAT post-translational modifications. HeLa
cells were lysed in ‘Mammalian Cell Lysis Buffer’ (Perbio) and
normalized levels of protein were protein gel blotted using
standard protocols. Primary antibodies against human β-ACTIN,
STAT1, pSTAT1, STAT3, pSTAT3, STAT5 and pSTAT5 were
purchased from Cell Signaling Technologies and used at a 1:1000
dilution. The activity of HRP-conjugated secondary antibodies
(Jackson Labs) was determined using ECL protein gel blotting
substrate (Pierce). Chemiluminescence was detected using either
film or a Luminescent Image Analyzer LAS-1000 (FUJIFILM)
and Intelligent Dark Box II (FUJIFILM).
Quantitative protein gel blot analysis. To quantitatively
determine the fold change in STAT and pSTAT after siRNA
treatment, bands were identified by thresholding a region of
interest comprising all bands using the “Triangle” algorithm34
that is based on normalization of height and dynamic range of
the image intensity histogram, as implemented in ImageJ.35 For
STAT3 and pSTAT3 protein gel blots and their corresponding
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β-ACTIN controls, thresholds determined using the “Triangle”
algorithm were used directly, whereas for STAT1 and pSTAT1
protein gel blots and their corresponding β-ACTIN controls,
15 a.u. were subtracted from the threshold determined by the
Triangle algorithm due to lower signal intensities. All pixels with
intensities above the threshold were assigned a value of 1, and all
pixels with intensities below the threshold were assigned a value
of 0. The original image was divided by this mask to prevent
pixels with intensities below the threshold from being considered
in further calculations. The average intensity in a smaller region
of interest around individual bands was calculated by summing
the intensities of the identified pixels (i.e., the total intensity of
the band) and dividing this sum by the number of pixels (i.e., the
area occupied by the band). We then calculated the ratio of
STAT and pSTAT protein levels relative to β-ACTIN levels and
normalized these values to those from control samples on the
same protein gel blot to determine fold change.
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